Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Group 1 - Adverum Biotechnologies (ADVM) has shown a year-to-date performance increase of approximately 135.1%, significantly outperforming the average return of 6.6% for Medical companies [2][3] - The Zacks Consensus Estimate for ADVM's full-year earnings has increased by 5.2% over the past quarter, indicating improved analyst sentiment and earnings outlook [2] - Adverum Biotechnologies holds a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Group 2 - Adverum Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 512 companies and currently ranks 90 in the Zacks Industry Rank [3] - The average performance of the Medical - Biomedical and Genetics industry has seen a decline of 0.9% year-to-date, highlighting ADVM's relative strength within the sector [3] - Another notable performer in the Medical sector is Arcutis Biotherapeutics, Inc. (ARQT), which has achieved a year-to-date increase of 216.9% and also holds a Zacks Rank of 2 (Buy) [2][3]